Key result
HIV infection linked to ~15-point lower rate of 12-month blood pressure control.
Why the study?
Hypertension is an increasingly important comorbidity among people living with HIV in sub-Saharan Africa. Although regular HIV clinic attendance and established chronic care systems might be expected to support better blood pressure control, existing evidence remains inconsistent.
Does HIV status affect blood pressure control at 12 months in adults with hypertension in Tanzania and Uganda?
RCT (n=2,391)
Cluster-randomised
Yes
Does HIV status affect blood pressure control at 12 months in adults with hypertension in Tanzania and Uganda?
Adults with hypertension living with HIV in Tanzania and Uganda had persistently poorer blood pressure control at baseline and 12 months compared to those without HIV, highlighting the need to strengthen integrated hypertension management within HIV services.
Answers are grounded in this paper and cite their sources.
Hypertension control appears worse among PLHIV; hypothesis-generating for integrated HIV-hypertension care models.
Hypertension is an increasingly important comorbidity among people living with HIV (PLHIV) in sub-Saharan Africa. Although regular HIV clinic attendance, more frequent healthcare contact, and established chronic care systems might be expected to support better blood pressure (BP) control, existing evidence remains inconsistent. We compared BP outcomes between PLHIV and those without HIV within a common trial setting. We conducted a secondary analysis of a pragmatic cluster-randomised trial undertaken in 32 health facilities in Tanzania and Uganda between 30 June 2020 and 1 April 2021. Adults aged ≥ 18 years with hypertension were included, irrespective of HIV or diabetes status, and followed for 12 months under integrated or standard care. The primary outcome was BP control at 12 months, defined as < 140/90 mmHg. Generalized estimating equations (GEE) were used to compare outcomes by HIV status, accounting for clustering at the health-facility level and adjusting for age, sex, trial arm and site location. Among 2,391 participants with 12-month blood pressure data, 453 were PLHIV and 1,938 were without HIV. Blood pressure control was achieved in 32.7% (148/453) of PLHIV compared with 46.9% (909/1,938) of those without HIV, with an adjusted risk difference of 14.5% points (95% CI 9.5, 19.5) favouring participants without HIV. At 12 months, mean systolic BP was higher among PLHIV than those without HIV (144.4 [SD 23.6]) mmHg vs. 139.5 (SD 20.9) mmHg, with an adjusted mean difference of -5.6 mmHg (95% CI -8·1, -3·1). Mean diastolic BP was also higher among PLHIV (92.6 [SD 14.5]) mmHg vs. 85.6 (SD 11.8) mmHg, with an adjusted mean difference of -5.1 mmHg (95% CI -6·7, -3·5). These differences were present at enrolment and remained across age and sex groups during follow-up. Participants living with HIV entered the trial with poorer BP control profiles than those without HIV, and these differences remained evident at 12 months. This persistent disparity highlights the need to strengthen long-term hypertension management among PLHIV and to further integrate hypertension care within HIV services in these settings.
No takes yet. Share an insight, caveat, or question.
Kivuyo et al. (2026) conducted an RCT in Hypertension (n=2,391). Living with HIV (PLHIV) vs. Adults without HIV was evaluated on Blood pressure control (<140/90 mmHg) at 12 months (Adjusted risk difference 14.5% points, 95% CI 9.5-19.5). Adults living with HIV had lower 12-month BP control (<140/90 mmHg) than those without HIV.
Synapse has enriched 10 related papers. Consider them for comparative context: